The average one-year price target for Arrowhead Pharmaceuticals (NasdaqGS:ARWR) has been revised to $77.60 / share. This is an increase of 23.01% from the prior estimate of $63.08 dated December 18, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $35.35 to a high of $115.50 / share. The average price target represents an increase of 18.40% from the latest reported closing price of $65.54 / share.
What is the Fund Sentiment?
There are 547 funds or institutions reporting positions in Arrowhead Pharmaceuticals. This is an increase of 14 owner(s) or 2.63% in the last quarter. Average portfolio weight of all funds dedicated to ARWR is 0.14%, an increase of 31.09%. Total shares owned by institutions increased in the last three months by 3.79% to 130,331K shares. 
The put/call ratio of ARWR is 0.49, indicating a bullish outlook.
What are Other Shareholders Doing?
Avoro Capital Advisors holds 10,900K shares representing 7.93% ownership of the company. In its prior filing, the firm reported owning 10,600K shares , representing an increase of 2.75%. The firm increased its portfolio allocation in ARWR by 65.68% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 7,520K shares representing 5.47% ownership of the company. In its prior filing, the firm reported owning 7,840K shares , representing a decrease of 4.26%. The firm increased its portfolio allocation in ARWR by 17.94% over the last quarter.
Slate Path Capital holds 4,982K shares representing 3.63% ownership of the company. In its prior filing, the firm reported owning 5,232K shares , representing a decrease of 5.02%. The firm increased its portfolio allocation in ARWR by 86.54% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,872K shares representing 2.82% ownership of the company. In its prior filing, the firm reported owning 3,399K shares , representing an increase of 12.20%. The firm increased its portfolio allocation in ARWR by 26.03% over the last quarter.
Geode Capital Management holds 3,131K shares representing 2.28% ownership of the company. In its prior filing, the firm reported owning 2,979K shares , representing an increase of 4.87%. The firm increased its portfolio allocation in ARWR by 10.94% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
